A primer on medieval chants, minimalist opera and everything in between. By Mitchell Kuga The origins of what we think of as Western classical music date back to the 10th century, with the development ...
Can a handful of atoms outperform a much larger digital neural network on a real-world task? The answer may be yes. In a study published in Physical Review Letters, a team led by Prof. Peng Xinhua and ...
Scientists pinpoint a skin alarm system pathway that links local damage to systemic immune responses
Skin, our largest organ, acts as a protective barrier against pathogens that try to invade our bodies while constantly monitoring for potential threats. In the skin's outermost layer, the epidermis, ...
The mystery of how stress exacerbates atopic dermatitis, more commonly known as eczema, may be closer to being understood. A new study published in the journal Science has identified a specific nerve ...
After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...
Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...
A study published in Nature Medicine identified a link between the placebo effect and immune system function. In the experiment, individuals who generated positive expectations showed a stronger ...
Readers discuss ways to rescue the industry. To the Editor: Re “Stop Mutilating Classical Music to Sell It to Kids,” by Evan Shinners (Opinion guest essay, Jan. 23): Mr. Shinners’s essay makes an ...
Pour one out for the ancient MetroCard and its equally old cousin, the PATH SmartLink card. The beginning of the end for these longtime ways to pay fares on the bi-state PATH system came Thursday when ...
In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies ...
Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results